Entera Bio Ltd. (ENTXW): Nasdaq/NYSE listing notice — Entera Bio receives Nasdaq delinquency notice for minimum bid price non-compliance

Entera Bio Ltd.

Nasdaq notified Entera Bio on Nov 21, 2022 that ordinary shares fail minimum $1.00 bid price for 30 consecutive business days.
Company has 180 calendar days, until May 22, 2023, to regain compliance with minimum bid price requirement.
To cure, closing bid must be at least $1.00 for a minimum of 10 consecutive business days before deadline.
If non-compliant by May 22, 2023, Entera may seek an additional 180-day period subject to meeting other listing standards.
Notice has no immediate effect on the company's business operations.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Entera Bio Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 21, 2022, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s ordinary shares, par value of NIS 0.0000769 per share (the “ ordinary shares ”), fail to comply with the $1.00 minimum bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the ordinary shares for the 30 consecutive business days prior to the date of the Notice. Pursuant to Nasdaq Listing

View on SEC.gov

Browse all listing & compliance notices →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-22-004137

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.